Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SAIC | PRESS-RELEASE | bullish | 7/10 | SAIC reported Q1 FY2027 (period ending May 1, 2026) with adjusted diluted EPS of $3.23, a 68% YoY increase, and revenues | Jun 1, 2026 |
| IVVD | PRESS-RELEASE | bullish | 5/10 | Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. | Jun 1, 2026 |
| WALD | PRESS-RELEASE | bullish | 7/10 | Waldencast has agreed to sell its Obagi Medical business to Bridgepoint for up to $460 million enterprise value, with pr | Jun 1, 2026 |
| LBTYA | PRESS-RELEASE | bullish | 7/10 | Liberty Global announced the formation of Ziggo Group, a new Benelux telecom entity combining VodafoneZiggo and Telenet, | Jun 1, 2026 |
| AUUD | PRESS-RELEASE | neutral | 3/10 | Auddia announced a 12-month Full Platform Partnership between its Discovr Radio platform and Beatcave, Canada's leading | Jun 1, 2026 |
| ACON | PRESS-RELEASE | neutral | 3/10 | Aclarion announced that its Nociscan MRS technology was used in an award-winning research study exploring immune-associa | Jun 1, 2026 |
| AGIO | PRESS-RELEASE | mixed | 6/10 | Agios Pharmaceuticals licensed exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for immune | Jun 1, 2026 |
| WTW | PRESS-RELEASE | neutral | 2/10 | Willis Towers Watson published its annual Directors and Officers Liability Insurance Survey, highlighting that geopoliti | Jun 1, 2026 |
| THCH | PRESS-RELEASE | neutral | 1/10 | TH International Limited announced it will report its Q1 2026 results on June 9, 2026. | Jun 1, 2026 |
| BZ | PRESS-RELEASE | neutral | 3/10 | Kanzhun Limited (BZ) disclosed continued share repurchases, spending over RMB40.6 million (~$5.7M) on May 29, 2026, brin | Jun 1, 2026 |
| BIIB | PRESS-RELEASE | mixed | 5/10 | Biogen and UCB announced publication of full Phase 3 PHOENYCS GO results for dapirolizumab pegol (DZP) in The Lancet, sh | Jun 1, 2026 |
| NVDA | PRESS-RELEASE | neutral | 4/10 | NVIDIA announced the RTX Spark superchip for Windows PCs, designed for personal AI agents, with up to 1 petaflop AI perf | Jun 1, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented extended Phase 1 data for its TCR bispecific IMA401 at ASCO 2026, showing a 29% confirmed ORR and 64% | May 31, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines reported overwhelmingly positive Phase 3 data for daraxonrasib in metastatic pancreatic cancer, sho | May 31, 2026 |
| REPL | PRESS-RELEASE | bullish | 6/10 | Replimune presented final Phase 1 data for RP2 (alone and with nivolumab) at ASCO 2026, showing durable responses in hea | May 31, 2026 |
| IMCR | PRESS-RELEASE | bullish | 6/10 | Immunocore presented updated Phase 1 data for brenetafusp in heavily pretreated advanced melanoma at ASCO 2026, showing | May 31, 2026 |
| EIKN | PRESS-RELEASE | neutral | 5/10 | Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing | May 30, 2026 |
| BNTX | PRESS-RELEASE | bullish | 7/10 | BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in firs | May 30, 2026 |
| MLYS | PRESS-RELEASE | bullish | 7/10 | Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 2026, showing lorundros | May 30, 2026 |
| IMTX | PRESS-RELEASE | bullish | 7/10 | Immatics reported updated Phase 1 data for IMA203CD8 PRAME cell therapy at ASCO 2026, showing 63% ORR (50% cORR) in heav | May 30, 2026 |
| REPL | PRESS-RELEASE | bullish | 8/10 | Replimune presented 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti-PD-1-faile | May 30, 2026 |
| COGT | PRESS-RELEASE | bullish | 8/10 | Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib i | May 30, 2026 |
| FCHL | PRESS-RELEASE | bearish | 7/10 | Fitness Champs Holdings received a Nasdaq deficiency letter for failing to meet the minimum $2.5M stockholders' equity r | May 29, 2026 |
| CETY | PRESS-RELEASE | bearish | 7/10 | Clean Energy Technologies disclosed a Nasdaq deficiency notice for late filing of its Q1 2026 10-Q, with a 60-day cure p | May 29, 2026 |
| CELU | PRESS-RELEASE | bearish | 6/10 | Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure | May 29, 2026 |
| RXRX | PRESS-RELEASE | neutral | 2/10 | Recursion Pharmaceuticals granted inducement RSU awards covering ~2.99 million shares to 33 new employees under its 2024 | May 29, 2026 |
| GURE | PRESS-RELEASE | bearish | 7/10 | Gulf Resources received a second Nasdaq delinquency notice for failing to file its Q1 2026 Form 10-Q, compounding an exi | May 29, 2026 |
| AAUC | PRESS-RELEASE | bullish | 6/10 | Allied Gold announced that Zijin Gold has received Investment Canada Act approval for its acquisition of the company, an | May 29, 2026 |
| FLUT | PRESS-RELEASE | bullish | 6/10 | Flutter Entertainment reported Q1 2026 EPS of $1.22, a 144.3% beat vs the $0.50 consensus, on revenue of $4.26B (in line | May 29, 2026 |
| OCS | PRESS-RELEASE | bearish | 7/10 | Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edema (DME) failed to me | May 29, 2026 |